Literature DB >> 23429551

What the infectious disease physician needs to know about pegylated interferon and ribavirin.

Naveen Gara1, Marc G Ghany.   

Abstract

The treatment of chronic hepatitis C is rapidly evolving from triple therapy to regimens that do not require interferon or even ribavirin. However, pegylated interferon and ribavirin will remain the backbone of hepatitis C therapy for the time being. This review summarizes the pharmacokinetics of peginterferon and ribavirin with a particular emphasis on their side-effect profile and management. Finally, the continued role of peginterferon and ribavirin in future therapies will be discussed.

Entities:  

Keywords:  adverse events; chronic hepatitis C treatment; peginterferon; ribavirin

Mesh：

Substances：

Year:  2013        PMID： 23429551      PMCID： PMC3641865          DOI： 10.1093/cid/cit074

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  46 in total

Review 1.  Mechanism of action of ribavirin in the combination treatment of chronic HCV infection.

Authors:  Johnson Y N Lau; Robert C Tam; T Jake Liang; Zhi Hong
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

2.  Paroxetine for the prevention of depression induced by interferon alfa.

Authors:  M R Kraus; A Schäfer; M Scheurlen
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

3.  Weight loss in HIV-infected patients.

Authors:  Teresa Garcia-Benayas; Francisco Blanco; Vincent Soriano
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

4.  Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.

Authors:  Martin Schaefer; Rahul Sarkar; Viola Knop; Susanne Effenberger; Astrid Friebe; Loni Heinze; Ulrich Spengler; Thomas Schlaepfer; Jens Reimer; Peter Buggisch; Johann Ockenga; Ralph Link; Michael Rentrop; Hans Weidenbach; Gwendolyn Fromm; Klaus Lieb; Thomas F Baumert; Andreas Heinz; Thomas Discher; Konrad Neumann; Stefan Zeuzem; Thomas Berg
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

7.  Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.

Authors:  Martin Schaefer; Folkhard Schmidt; Christian Folwaczny; Reinhard Lorenz; Gaby Martin; Norbert Schindlbeck; Walter Heldwein; Michael Soyka; Heinz Grunze; August Koenig; Klaus Loeschke
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

8.  Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

Authors:  Alejandro Soza; James E Everhart; Marc G Ghany; Edward Doo; Theo Heller; Kittichai Promrat; Yoon Park; T Jake Liang; Jay H Hoofnagle
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 9.  Pure red cell aplasia secondary to treatment with erythropoietin.

Authors:  Francesco Locatelli; Lucia Del Vecchio
Journal:  J Nephrol       Date:  2003 Jul-Aug       Impact factor: 3.902

10.  Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.

Authors:  Mark S Sulkowski; Fred Poordad; Michael P Manns; Jean-Pierre Bronowicki; K Rajender Reddy; Stephen A Harrison; Nezam H Afdhal; Heather L Sings; Lisa D Pedicone; Kenneth J Koury; Vilma Sniukiene; Margaret H Burroughs; Janice K Albrecht; Clifford A Brass; Ira M Jacobson
Journal:  Hepatology       Date:  2013-02-11       Impact factor: 17.425
View more
  9 in total

Review 1.  In vitro fertilization for women infected by hepatitis C virus: a matched case-control study and a systematic literature review.

Authors:  Chloë Shaw-Jackson; Mélissa Capraro; Lieveke Ameye; Jean Vandromme; Yannick Manigart; Serge Rozenberg; Candice Autin
Journal:  J Assist Reprod Genet       Date:  2017-02-24       Impact factor: 3.412

2.  KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy.

Authors:  A Rivero-Juarez; R Gonzalez; M Frias; B Manzanares-Martín; D Rodriguez-Cano; I Perez-Camacho; A Gordon; F Cuenca; A Camacho; J A Pineda; J Peña; A Rivero
Journal:  Pharmacogenomics J       Date:  2016-03-15       Impact factor: 3.550

Review 3.  Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.

Authors:  Clemens Stockklausner; C M Duffert; H Cario; R Knöfler; W Streif; A E Kulozik
Journal:  Ann Hematol       Date:  2021-03-12       Impact factor: 3.673

4.  Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C.

Authors:  Nathália Delvaux; Vanessa Duarte da Costa; Maristella Matos da Costa; Livia Melo Villar; Henrique Sérgio Moraes Coelho; Eliane Bordalo Cathalá Esberard; Priscila Pollo Flores; Carlos Eduardo Brandão-Mello; Cristiane Alves Villela-Nogueira; Adilson José de Almeida; Elisabeth Lampe
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-07-07       Impact factor: 2.743

Review 5.  Antiviral Treatment Guidelines for Middle East Respiratory Syndrome.

Authors:  Yong Pil Chong; Joon Young Song; Yu Bin Seo; Jae-Phil Choi; Hyoung-Shik Shin
Journal:  Infect Chemother       Date:  2015-09-30

Review 6.  Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.

Authors:  Jordan J Feld; Ira M Jacobson; Mark S Sulkowski; Fred Poordad; Fernando Tatsch; Jean-Michel Pawlotsky
Journal:  Liver Int       Date:  2016-09-29       Impact factor: 5.828

7.  The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015.

Authors:  Ji Yeon Lee; You-Jin Kim; Eun Hee Chung; Dae-Won Kim; Ina Jeong; Yeonjae Kim; Mi-Ran Yun; Sung Soon Kim; Gayeon Kim; Joon-Sung Joh
Journal:  BMC Infect Dis       Date:  2017-07-14       Impact factor: 3.090

Review 8.  Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials.

Authors:  Young-Mo Yang; Eun Joo Choi
Journal:  Ther Clin Risk Manag       Date:  2017-04-12       Impact factor: 2.423

Review 9.  Middle East Respiratory Syndrome Virus Pathogenesis.

Authors:  Sunit K Singh
Journal:  Semin Respir Crit Care Med       Date:  2016-08-03       Impact factor: 3.119
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.